NCT01487798 - Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic human insulin 30

Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2

DRUG

biphasic insulin aspart 30

Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2

Trial Locations (17)

BL1 4QS

Novo Nordisk Investigational Site, Bolton

CF14 4XW

Novo Nordisk Investigational Site, Cardiff

DE7 1DY

Novo Nordisk Investigational Site, Derby

DD1 9SY

Novo Nordisk Investigational Site, Dundee

EX2 5AX

Novo Nordisk Investigational Site, Exeter

EIRE

Novo Nordisk Investigational Site, Galway

G4 0SF

Novo Nordisk Investigational Site, Glasgow

LE1 5WW

Novo Nordisk Investigational Site, Leicester

L7 8XP

Novo Nordisk Investigational Site, Liverpool

NW10 7NS

Novo Nordisk Investigational Site, London

SE1 7EH

Novo Nordisk Investigational Site, London

NE7 7DN

Novo Nordisk Investigational Site, Newcastle

NG7 2UH

Novo Nordisk Investigational Site, Nottingham

S5 7AU

Novo Nordisk Investigational Site, Sheffield

L49 5PE

Novo Nordisk Investigational Site, Upton

CH63 4JY

Novo Nordisk Investigational Site, Wirral, Merseyside

YO3 7HE

Novo Nordisk Investigational Site, York